Barnett Technical Services

Silver Spring, MD 20910

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $0.0
First Award Date 09/30/86
Most Recent Award Date 06/21/91

Key Personnel

Last Name Name Awards Contact
Barnett Beth Barnett 5

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/21/91 - 06/30/92

The purpose of this project is to demonstrate computerized instruction on cancer prevention for minority and low SES children. Both race and lower SES are associated with elevated cancer mortality rate; lack of early detection is a key factor. Teaching children in school reaches the greater number of lower SES and minorities with information a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/89 - 03/31/91

Current information sources on questionable and unproven cancer treatments are limited in availability and generally lack critical content. Physicians, Congress, FDA and the public have recognized the need to have quality critical information in order to make informed decisions about these therapies. Phase I demonstrated the feasibility of dev...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/88 - 08/31/89

Current information sources on questionable and unproven cancer treatments are limited in availability and generally lack critical content. Physicians, Congress, FDA and the public have recognized the need to have quality critical information in order to make informed decisions about these therapies. Phase I demonstrated the feasibility of dev...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/88 - 08/31/89

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/86 - 07/31/87

Current sources of information on questionable medical modalities are limited in availability and generally lack critical content. This project will develop the capacity to provide easily accessible online comprehensive and detailed inquiry responses to physicians. The central issue of how to critically evaluate therapies that for the most par...